To describe the outcome and complications following ethanolamine oleate treatment of venous malformations. METHODS: Seventy-two patients (27 male, 45 female; age range, 3 months to 16 years) with 76 lesions were treated with ethanolamine oleate at 0.50-16 mL per session, with a maximum dose of 0.40 mL/kg. All patients were evaluated 8 weeks after the final injection and were followed-up for about 1 year. All the patients were treated on a day-case basis except for one who required general anaesthesia. RESULTS: Seventy-six lesions underwent 149 sclerotherapy sessions, with 41 requiring one session, 21 requiring two and 14 requiring more than two. Ethanolamine oleate significantly improved five lesions and completely resolved symptoms in 71. All patients experienced pain and swelling to a variable degree for a short time. Skin sloughing took place in three patients. No other complications were observed. CONCLUSION: Treatment of venous malformations with ethanolamine oleate is safe and effective. [Asian J Surg 2008;31(4):220-4] 
Introduction
Cavernous haemangioma may have discrete or diffuse lesions. Surgery is often curative, but larger diffuse lesions and those in inaccessible sites may not be removed completely and have a higher propensity for recurrence. Venous malformations are low-flow vascular malformations that can cause significant clinical problems and are sometimes difficult to treat. They may be present at birth but may not always be evident. 1 Venous malformations occur equally in both sexes, never regress and may increase in size. They can present as single or multiple lesions in any part of the body: face, oral cavity, tongue, limbs, trunk, pharynx, genitalia, urinary bladder, brain, spinal cord, liver, lungs, skeletal muscles and bones. They can be cosmetically inconsequential or very distorting. 1 Venous malformations are wrongly classified in medical parlance and the literature as cavernous haemangioma. History and physical examination can lead to a diagnosis of venous malformation. 1 At present, therapeutic options for venous malformation are: sclerotherapy, surgery, combined surgery and sclerotherapy, embolization and laser therapy. Such a range of treatment modes reflects the fact that no single approach is entirely satisfactory for the treatment of venous malformation. Surgery can be curative but may not be possible in all cases, in particular in large malformations and for those in inaccessible sites such as the oropharynx, mediastinum and oesophagus. Surgical treatment is also costly, risky, time-consuming, causes psychological distress to the patients and their parents, and may require a long hospital stay. Laser therapy is costly and also inadequate for all but the thinnest lesions. 2 (Table 1) . Postoperative patients with recurrent and residual venous malformations were also included. Patients associated with other diseases, such as respiratory tract infection (RTI) and pyrexia of unknown origin (PUO) were excluded from the study.
Patients with a history of previous infections or venous malformations were excluded to avoid confusion. A total of 72 patients with 76 lesions were studied. Patients were diagnosed clinically, using investigations like Doppler ultrasonography and venography in some cases for documentation and academic purposes. Plain X-ray of relevant parts was done in a few cases to see the effects of venous malformations.
Patients were treated with intralesional injection of ethanolamine oleate not exceeding 0.4 mL/kg on multiple sites of the lesion with a 23G or hypodermic (26G) needle until slight elevation of the lesion. 11 Patients were allowed to go home a few hours after treatment. They were observed on days 3 and 7 and advised to report any complications. In the case of small lesions in relation to body weight, which can be treated in a single session, the effects of ethanolamine oleate and reduction in venous malformation size were investigated 8 weeks after the final treatment session. If the initial procedure could not treat the whole lesion, patients were advised to attend at 3-week intervals for subsequent treatments and follow-up was at 8 weeks after the final session. For large diffuse lesions, up to 12 treatments were performed.
Results
Out of 76 lesions, 42 (55.26%) were present at birth. The remainder appeared at different times after birth. The lesions varied in size and shape, and were focal, diffuse, serpentine or cystic. The most common site of occurrence was the craniofacial area, with 41 lesions (54%). Venous malformations were also present in the axilla, trunk, limbs, genitalia and perineum ( Table 2) . Four of the 76 lesions were initially treated with steroids followed by surgery, at least 6 months previously. In all of these cases, the lesions were non-responsive to steroids and surgery was inadequate. Another two lesions were previously treated surgically but recurred after 6 and 8 months respectively. Thirty-two lesions were treated with oral steroids at least 3 months beforehand, four were also treated with intralesional steroids at least 3 months previously, and 34 had no history of treatment ( Figure 1) .
The injection dose and frequency of ethanolamine oleate depended on the site and size of the lesions and the 6.01 ± 0.69 mL) per session. All of the procedures were performed on a day-case basis without anaesthesia, except for one patient with two lesions in the oral cavity, who was treated under general anaesthesia. Forty-one lesions regressed after a single injection. The rest needed multiple sessions, the highest number of sessions being 12 (mean, 2.47).
Response
All of the lesions responded to ethanolamine oleate sclerotherapy (Figures 2-6 ). Responses were evaluated 8 weeks after the final injection session. Responses were graded into four groups: excellent, complete regression; good response, > 50% regression; poor response, < 50% regression; no response. Seventy-one of the 76 lesions were completely cured and the remaining five lesions (which were diffuse) showed a significant improvement (Table 3) .
Skin necrosis occurred in four patients: one with full thickness in a small area, and three with partial thickness which were resolved conservatively without surgical intervention. No other side effects were observed. The site of the lesion did not have any bearing on the outcome of sclerotherapy. There were no age and sexual variations in responses. In four cases, there was firm-to-hard, noncompressible residual fibrosis tissue. All of the patients Before After Figure 5 . Right parotid area before and 8 weeks after last injection of ethanolamine oleate.
Before After were followed-up for at least 1 year, i.e. 14 months after the final injection. There was no recurrence. All of our patients responded to ethanolamine oleate, which correlates with the results of other studies. 2, 4, 7, 8, [15] [16] [17] [18] All patients observed swelling after injections, which also correlated with other studies. 10 Side effects noted included epithelial sloughing, which healed spontaneously. No other side effects were observed in our study and the rate of complications did not differ from that of other studies. 16 The results of the present and previous studies show that sclerotherapy with ethanolamine oleate is effective for the treatment of venous malformations.
Discussion
In conclusion, sclerotherapy with ethanolamine oleate is effective and reasonably safe for the treatment of venous malformations, although on some occasions, injections had to be repeated. However, the long-term safety and efficacy of ethanolamine oleate should be further evaluated in a larger series of cases over a longer period of follow-up. 
